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Overview of clinical types and the genetics of 
epilepsy
The  International  League  Against  Epilepsy  defines  an 
epileptic seizure as ‘a transient occurrence of signs and/
or symptoms due to abnormal excessive or synchronous 
neuronal  activity  in  the  brain’  [1,2].  The  condition  is 
common, with prevalence around 1% and lifetime inci­
dence around 3% [3]. Most epilepsies can be broadly and 
easily classified based on their pattern of electroclinical 
onset  as  either  generalized  (‘originating  at  some  point 
from within, and rapidly engaging, bilaterally distributed 
networks’) or focal (‘originating within networks limited 
to  one  hemisphere’)  [1].  Within  each  of  these  broad 
classifications  are  multiple  distinct  syndromes,  more 
than half of which are considered to be ‘genetic epilepsies’. 
In older terminology, genetic epilepsies were referred to 
as ‘idiopathic epilepsies’ [4]. Syndromes, and sometimes 
subsyndromes,  are  delineated  when  the  seizures  are 
defined by easily recognizable electroclinical features and 
similar enough to be regarded as a homogeneous group, 
distinct from other groups in the same classification level 
(Table 1). For example, genetic generalized epilepsies are 
frequently divided into their subsyndromes of childhood 
absence epilepsy, juvenile absence epilepsy, juvenile myo­
clonic epilepsy and generalized tonic clonic seizures.
There is a subset of epilepsy syndromes that are clearly 
monogenic, and traditional linkage studies in large families 
have  been  useful  for  identifying  causative  genes  [5,6]. 
However, the vast majority of the genetic epilepsies are 
multifactorial,  with  an  underlying  genetic  contribution 
that is polygenic, where few or usually none of the sus­
cep  tibility genes have been identified. This multifactorial 
concept dates back to the early works of William Lennox 
[7]  and  was  well  established  in  the  modern  era  with 
additional  twin  data  [8].  It  is  important  to  note  that 
epilepsy with complex genetics and complex epilepsy are 
distinct concepts. To the geneticist, complex epilepsy is 
epilepsy  with  complex  genetics;  that  is,  multifactorial 
epilepsy  that  is  polygenic  and  influenced  by  environ­
mental  effects,  both  internal  and  external.  Complex 
epilepsy to the epileptologist, on the other hand, refers to 
the complexity of the seizure pattern. Without an appre­
cia  tion of the difference, interactions between basic and 
clinical scientists can be, and have been from personal 
experience,  confused  by  ‘complex  epilepsy’  meaning 
differ  ent things to different people. In the context of this 
article, complex epilepsy will mean that which is multi­
factorial in origin, rather than necessarily having complex 
seizure patterns.
Monogenic epilepsies
To date, more than 20 genes have been identified for the 
group of genetic epilepsies that are primarily monogenic 
[5,6,9,10], prompting a recent update of clinically based 
classification [1]. While individual syndromes that com­
prise  each  of  these  groups  are  generally  diagnosed 
through clinical assessment, molecular testing now facili­
tates  more  accurate  definition  of  clinically  similar 
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of  different  genes.  While  gene  identity  provides  an 
alternative or additional criterion for syndrome classifica­
tion,  it  also  has  clinical  efficacy  ­  providing  a  rapid 
definitive diagnosis to obviate an otherwise circuitous set 
of  invasive  or  costly  investigative  procedures.  Further­
more,  in  some  cases,  specific  therapeutic  intervention 
can be enabled to achieve improved outcomes or more 
accurate prognosis. Genetic testing for the epilepsies has 
high  clinical  utility  in  cases  that  may  involve  SLC2A1 
(glucose transporter type 1 deficiency), SCN1A (Dravet 
syndrome),  PCDH19  (familial  epilepsy  and  mental  re­
tard  ation limited to females, ‘Dravet­like’ PCDH19 syn­
drome), ARX (X­linked infantile spasms and myoclonic 
seizures,  dystonia,  and  X­linked  lissencephaly  with 
ambigu  ous genitalia) or STK9 (X­linked infantile spasms) 
mutations. Testing has high analytical sensitivity (ability 
to detect the presence of a causative mutation) and high 
analytical  specificity  (ability  to  exclude  mutation  in  a 
candidate gene) for all of the monogenic epilepsies, but 
not necessarily high clinical utility apart from some of the 
syndromes  associated  with  the  above  genes  [9].  It  has 
little or no clinical utility at this time when knowledge of 
the  gene  is  not  needed  for  accurate  syndrome  classi­
fication, when knowledge of the gene does not direct or 
affect  treatment,  or  in  cases  of  genetically  complex 
epilepsies triggered by the combined effects of multiple 
genes spread across the genome, most likely each having 
only a small effect on phenotype.
Complex epilepsies
Speculation of the genetic architecture for the genetically 
complex  epilepsies  centers  on  the  common  disease­
common variant hypothesis [11] and the common disease­
rare variant hypothesis [12]. The general failure of linkage 
and association studies applied to the complex epilepsies 
[13­16]  argues  against  the  common  disease­common 
variant hypothesis, although the major criticism of such 
studies  is  that  they  are  underpowered  to  detect  the 
magnitude of odds ratios that are likely associated with 
susceptibility variants in the genetically complex epilepsies 
[17] and indeed other neuropsychiatric brain disorders.
The  common  disease­rare  variant  hypothesis,  which 
suggests a variable subset of multiple rare genetic vari­
ants,  has  greater  appeal  for  complex  epilepsy  [18,19], 
especially given the failure of association studies, which 
work on the premise of the common disease­common 
variant hypothesis [16], to deliver consistent findings. A 
mixture of the two models is also entirely plausible [19] 
with  functional  differences  in  the  electrophysiological 
properties of ion channels demonstrated for both rare and 
polymorphic  genetic  variation  detected  at  the  GABRD 
(encoding γ­aminobutyric acid A receptor, δ), CACNA1H 
(encoding  calcium  channel,  voltage­dependent,  T  type, 
α 1H subunit) and CLCN2 (encoding chloride channel 2) 
genes [20­23], for example. Computer simulation supports 
the notion that genetic variations associated with only 
very small functional changes in ion channel properties 
are  sufficient  to  make  meaningful  contributions  to 
increasing susceptibility to epilepsy [24].
Multiple  sclerosis  is  another  disorder  with  complex 
inheritance where extensive study suggests ‘risk variants 
likely to include hundreds of modest effects and possibly 
thousands of very small effects’ [25]. Similar conclusions 
with systematic effects of multiple rare variants across 
the genome have been suggested for schizophrenia and 
bipolar disorder [26]. We predict the same for epilepsy 
with  complex  inheritance,  with  seizure  susceptibility 
thresh  olds determined by combinations of many rare to 
moderately  common  sequence  variants,  copy  number 
variants (CNVs) and perhaps non­coding DNA sequen­
ces  with  functional  effects.  Weak  effects  will  only  be 
detectable  by  genome­wide  association  studies  using 
massive  sample  sizes.  Kryukov  et  al.  [27]  pre­empted 
out  comes from deep resequencing by massively parallel 
sequencing  (previously  referred  to  as  next­generation 
sequencing  [28])  by  promoting  an  association  study 
approach based on the premise of multiple rare variants 
present in susceptibility genes in higher numbers for a 
given disease group (for example, epilepsy) than in their 
corresponding controls. The statistical tools to support 
that approach are now surfacing [29].
The heritability of genetic generalized epilepsy suggests 
a major genetic component [8] but virtually none has yet 
been  identified.  This  constitutes  the  ‘dark  matter’  [30]. 
The task is to find this missing heritability and charac­
terize it in terms of number of loci, effect sizes, allelic 
frequencies  of  variants  and  the  nature  of  the  variants 
[31]. Areas being investigated include cis­acting genome­
wide regulatory variants [32], genome­wide copy number 
variants [33,34] as discussed below, and, in the future, 
next­generation sequencing [28].
Copy number variation in epilepsy
CNVs are deletions, duplications or insertions of DNA in 
the genome that range in size from approximately 1 kb to 
Table 1. Examples of genetic generalized and focal 
epilepsy syndromes
Generalized epilepsy  Focal epilepsy
Absence epilepsy  ADEAF
Juvenile myoclonic epilepsy  ADNFLE
Generalized tonic-clonic seizures  BECTS
  Landau-Kleffner syndrome
ADEAF, autosomal dominant epilepsy with auditory features; ADNFLE, 
autosomal dominant nocturnal frontal lobe epilepsy; BECTS, benign epilepsy 
with centrotemporal spikes. See Berg et al. [1] for additional details and 
subsyndromes.
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significance, and numerous studies have now established 
that  CNVs  are  dispersed  throughout  the  genomes  of 
healthy individuals and some CNVs are quite common 
[35­37]. Importantly, CNVs have also been identified as a 
significant source of mutation. Small CNVs may result in 
the  deletion  or  duplication  of  one  or  more  exons  of  a 
known disease gene, and there are now many examples in 
the literature. In patients with intellectual disability (ID) 
or  developmental  delay,  testing  for  large  CNVs  is  now 
commonplace,  as  large  CNVs  underlie  15%  to  20%  of 
cases of ID [38,39]. CNVs can be detected by targeted 
studies directed to specific known CNVs by techniques 
such as multiplex ligation­dependent probe amplification 
(MLPA). In the epilepsies, MLPA is generally targeted to 
exons  of  known  epilepsy  genes  to  detect  intragenic 
deletions or duplications [40­45], some of which are too 
small to be detected by genome­wide approaches.
Genome­wide methods to detect CNVs include array­
comparative genomic hybridization (array­CGH) and SNP 
genotyping arrays. These technologies can be targeted to 
specific chromosomal regions [43,45­49]. However, their 
real  power  lies  with  capability  for  genome­wide 
interrogation,  where  there  is  no  need  for  a  priori 
knowledge of where a lesion may lie [33,34,46,50]. Using 
that approach, Depienne et al. [46] discovered a Dravet­
like  syndrome  caused  by  severe  PCDH19  mutations  on 
chromosome X, and McMahon et al. [50] ‘rediscovered’ 
the  15q13.3  CNV  and  found  a  novel  10q21.2  micro­
duplication.  Mefford  et  al.  [33]  and  Heinzen  et  al.  [34] 
used genome­wide approaches to establish the extent of 
rare CNVs in the genetic epilepsies (see below). For CNVs 
with boundaries extending beyond the target gene, array­
CGH is a powerful tool for accurately determining size and 
gene content. Large epilepsy­associated CNVs detectable 
by  MLPA,  but  extending  well  beyond  the  one  gene  of 
special interest (for example, beyond SCN1A), can also be 
reliably detected by array technologies [40,43,45].
The role of CNVs in epilepsy has now been addressed 
by several groups using both targeted and genome­wide 
approaches. Helbig and colleagues [51] first directed our 
attention to the role of the 15q13.3 microdeletion in the 
etiology  of  epilepsy.  This  microdeletion  was  first 
described in a series of patients with ID, most of whom 
also  suffered  from  seizures  [52],  but  is  much  more 
common in epilepsy cohorts [51,53,54]. This is one of the 
most  prevalent  genetic  risk  factors  identified  for  the 
genetic generalized epilepsy syndromes. A range of rare 
mutations within SLC2A1 encoding the GLUT1 glucose 
transporter are at least as important within the childhood 
absence  epilepsy  subsyndrome  of  genetic  generalized 
epilepsy [55,56]. Although estimated confidence intervals 
are  broad,  the  estimated  odds  risk  ratio  of  68  (95% 
confidence interval 29 to 181) for the 15q13.3 deletion 
[54] greatly exceeds that of most common susceptibility 
variants detectable by genome­wide association studies 
in  disorders  other  than  epilepsy.  Despite  its  relative 
‘severity’  in  relation  to  risk,  its  frequency  in  epilepsy 
cohorts is relatively high at around 1.3%. Conversely, this 
variant  is  difficult  to  find  in  the  general  control 
population,  despite  the  screening  of  large  numbers  of 
controls, even though family studies following detection 
of  an  index  case  disclose  frequent  transmissions  from 
non­penetrant  carrier  parents  [54,57].  Moreover,  the 
position of the original mutation in the pedigree is often 
not  too  far  back  into  its  living  ancestry,  suggesting  a 
relatively  high  recurrent  mutation  rate.  Of  the  seven 
genes within the lesion, haploinsufficiency of CHRNA7 
(nicotinic acetylcholine receptor, α7) is considered to be 
the most likely pathogenic element, although it is not the 
only neuronally expressed gene affected by the deletion. 
Interestingly,  early  genome­wide  linkage  studies  impli­
cated the CHRNA7 region in juvenile myoclonic epilepsy 
[58], but this could not be replicated [59], and screening 
of CHRNA7 did not detect convincing mutations [60]. 
Could it be that the families studied by Elmslie et al. [58] 
contained  enough  families  segregating  the  15q13.3 
microdeletion to give a linkage signal?
Subsequent studies investigated the role of other large 
CNVs that had previously been associated with increased 
risk  of  ID,  autism  and  schizophrenia  [53].  Somewhat 
surprisingly, significant numbers of the same recurrent 
CNVs  involved  in  the  disorders  listed  above  were 
implicated as a component of the polygenic pathogenic 
genetic architecture in the clinically and genetically com­
plex (idiopathic) epilepsies. Two microdeletions commonly 
associated  with  epilepsy  are  at  15q11.2  and  16p13.11 
[33,34,53].  Together  with  the  15q13.3  microdeletion, 
their combined frequency in test populations of genetic 
generalized  epilepsy  is  approximately  3%  [33].  Other 
large  recurrent  CNVs  associated  with  ID,  autism  or 
schizophrenia that have also been detected in epilepsy 
are  at  1q21.1,  16p12,  22q11  and  two  regions  within 
16p11.2  [33,53].  These  CNVs  represent  clearly  defined 
genetic  determinants  that  overlap  with  a  number  of 
hitherto regarded distinct disorders comprising part or 
all of their genetic architectures. The three most common 
recurrent CNVs, which together account for up to 3% of 
epilepsies, are shown in Figure 1. Notably, the 15q13.3 
microdeletion has been consistently present in 0.5% to 
1% of all genetic generalized epilepsy cohorts but has not 
been seen in >3,000 patients who presented with focal 
epilepsy syndromes [34], and therefore it may be a risk 
factor  specifically  for  generalized  epilepsy  syndromes. 
Deletions at 16p13.11 and 15q11.2 have been found in 
both generalized and focal epilepsies [33,34,53].
The  large,  recurrent  CNVs  described  above  occur 
because  of  specific  genomic  architecture  at  each 
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naturally occur  ring sets of low copy repeats or segmental 
duplications  [61­63]  that  facilitate  non­allelic  homolo­
gous  recombina  tion  [64,65],  resulting  in  deletion  or 
duplication of the intervening unique sequence. There­
fore,  each  region  with  such  architecture  is  prone  to 
rearrange  ment  at  meiosis,  causing  recurrence  of  large 
CNVs  with  nearly  identical  breakpoints  in  unrelated 
individuals. Because CNVs at these rearrangement­prone 
regions  of  the  genome  occur  with  an  appreciable 
frequency,  it  has  been  possible  to  detect  a  statistically 
significant difference between cases and controls.
Apart from the recurrent CNVs discussed above, the 
rare  non­recurrent  CNVs  are  also  likely  to  play  a 
significant role in the genetic etiology of epilepsy. Two 
recent  studies  applied  genome­wide  technologies  to 
detect  CNVs  in  affected  individuals.  Heinzen  and 
colleagues [34] evaluated 3,812 individuals and found an 
enrichment of large (>1 Mb) deletions in affected individ­
uals, the majority of which were seen in one individual 
each. Mefford et al. [33] evaluated 517 individuals with 
various  types  of  epilepsy  and  found  that  nearly  10% 
carried  one  or  more  rare  CNVs  that  had  not  been 
previously found at an appreciable frequency in controls. 
Again, the majority of events were seen only once, and 
represent  a  subset  of  the  rare  non­recurrent  CNVs 
involving genes that have been implicated in ID, autism 
or schizophrenia.
Syndrome constellations associated with CNVs
Taken  literally,  a  constellation  is  a  number  of  stars 
grouped within an outline. Here, we regard the CNV as 
the  ‘outline’  encompassing  a  group  of  its  associated 
syndromes  comprising  the  syndrome  constellation. 
Different combinations of syndromes define the constel­
lations  that  are  packaged  within  different  CNVs.  The 
CNVs  can  be  recurrent  in  the  population,  and  any 
recurrent  CNV  located  in  a  given  region  is  virtually 
identical from patient to patient. The syndrome constel­
lations include one or more types of ID, dysmorphism, 
autism,  schizophrenia  and,  more  recently,  genetic 
generalized epilepsy. The various syndromes within the 
constellations  are  themselves  genetically  and  pheno­
typically heterogeneous, and in some cases have defined 
subsyndromes. For example, genetic generalized epilepsy 
consists of the subsyndromes childhood absence epilepsy, 
juvenile  absence  epilepsy,  juvenile  myoclonic  epilepsy 
and generalized tonic clonic seizures. Recurrent deletions 
at 15q13.3 (1.5 Mb, seven genes), at 16p13.11 (1.2 Mb, 
eight  genes)  and  at  15q11.2  (1.3  Mb,  four  genes)  are 
emerging as the most common genetic determinants for 
various  distinct  disorders  with  complex  inheritance. 
These  generally  include  intellectual  disability  with  or 
without dysmorphism, autism, schizophrenia or genetic 
generalized  or  focal  epilepsy.  Epilepsy  was  the  latest 
addition  to  the  constellations  of  syndromes  associated 
with  each  of  these  CNVs,  and  is  now  well  established 
Figure 1. Three ‘common’ recurrent microdeletions in epilepsy. Microdeletion of 15q13.3 (1.5 Mb) in a patient with absence epilepsy. 
Microdeletion of 16p13.11 (800 kb) in a patient with juvenile myoclonic epilepsy. Microdeletion of 15q11.2 (350 kb) in a patient with infantile 
seizures. Regions depicted for each panel are as follows: 15q13.3 deletion: chr15, 28.0 to 31.0 Mb; 16p13.11 deletion: chr16, 15.0 to 16.7 Mb; 
and 15q11.2 deletion: chr15, 20.2 to 20.8 Mb (National Center for Biotechnology Information Build 36/hg18). Red vertical lines represent array-
comparative genomic hybridization probes that are deleted. Segmental duplications are represented by orange, yellow and gray blocks. Note that 
blocks of segmental duplications flank each deleted region. Genes are represented in blue, with key proposed candidate genes in red.
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rarer recurrent CNVs at 1q21.1, 16p12 and two regions 
within 16p11.2 [33,53].
Given the comorbidity of ID and epilepsy, autism and 
ID,  and  autism  and  epilepsy,  for  example,  perhaps  it 
should  not  be  surprising  that  some  CNVs  cause  over­
lapping neuropsychiatric features in affected individuals. 
However,  it  seems  remarkable  that  the  same  CNV 
susceptibility  lesion  can  be  a  genetic  determinant  for 
apparently  disparate  conditions  (for  example,  only 
epilepsy in one patient, only schizophrenia in another). 
One possible explanation might be that odds risk ratios 
associated with disorders included within a given constel­
lation of syndromes is relatively high in the context of 
disorders with complex inheritance. For example, genetic 
generalized  epilepsy  has  an  odds  risk  ratio  of  68  (95% 
confidence interval 29 to 181) for the 15q13.3 deletion 
[54];  this  is  far  higher  than  for  susceptibility  variants 
generally  detected  in  complex  genetic  disorders. 
Certainly another possible explanation is the presence of 
as  yet  undetected  additional  genetic  or  epigenetic 
variants  that  influence  the  phenotypic  outcome.  All  of 
the  ‘common’  recurrent  CNVs  in  epilepsy  (15q13.3, 
16p13.11  and  15q11.2)  have  probably  been  identified 
already, given the extent of the array­CGH genome­wide 
searches  already  completed  [33,34].  Some  of  the  less 
common recurrent microdeletions at 1q21.1, 16p12 and 
two regions within 16p11.2 may be associated with their 
own multisyndrome constellations.
Rare  or  unique  non­recurrent  CNVs  are  collectively 
more common than the combined recurrent ones. These 
lesions provide a wealth of leads to candidate epilepsy 
genes within or closely adjacent to them. The number, 
frequency and distribution of each gene­bearing CNV 
are  consistent  with  the  common  disease­rare  variant 
model for the genetic architecture for complex epilepsy. 
Overall genetic profiles of susceptibility genes for each 
individual are likely to be unique and fit the polygenic 
heterogeneity concept [18]. Genes within these epilepsy­
associated CNVs and genes identified through massively 
parallel  sequencing  [66]  each  represent  independent 
oppor  tunities to break out of the ion channel paradigm 
that might potentially constrain our thinking when the 
genetic architecture of epilepsy might extend beyond ion 
channels.  Results  of  studies  performed  so  far  suggest 
that  haploinsufficiency  (deletions)  or  overexpression 
(duplica  tions)  of  some  of  the  genes  in  non­recurrent 
CNVs may elicit the same syndromes as those in their 
associated constellations.
There  are  two  common  threads  in  these  discussions. 
First, the constellations of syndromes associated with each 
recurrent CNV can include a range of diverse pheno  types, 
including, in most cases, some combination of ID, autism, 
schizophrenia and epilepsy. Each CNV probably elicits its 
own specific distribution of pheno  types and frequency of 
each  phenotype,  defining  the  associated  constellation. 
Second, the mechanism for genesis of this extreme clinical 
heterogeneity observed within virtually identical lesions is 
not yet known. Several mechanistic possibilities have been 
outlined [34,67­69] but none has been proven as a general 
mechanism, or even a mechanism specific to any given 
CNV. The clinical heterogeneity is likely to depend upon 
the nature of the other risk factors or genetic modifiers in 
the rest of the genome that alone or in combination may 
specify the phenotype.
Conclusions and future perspectives
The  concept  of  extensive  clinical  heterogeneity  in 
epilepsy associated with a well­defined genetic lesion is 
not new. Well known examples are genetic generalized 
epilepsy  with  febrile  seizures  plus  [19],  caused  by 
mutations  in  sodium  channel  genes,  and  recently, 
genetic generalized epilepsy caused by the 15q13.3 CNV 
[70].  These  observations  have  challenged  complete 
reliance  on  the  phenotype­first  approach  to  diagnosis. 
Investigations  will  always  begin  with  general  clinical 
evaluation  to  broadly  classify  cases  into  disease 
categories.  Taking  genetic  generalized  epilepsy  as  an 
example, is it then necessary to further refine down to 
subsyndromes using clinical criteria alone, and to even 
contemplate  endo  phenotyping  for  deeper  clinical 
refinement? The answer is clearly no in the context of 
syndromic  constellations  associated  with  some  CNVs 
and phenotypic spectrums associated with some familial 
missense mutations. The aim of that exercise of making 
phenotypes as clinically homogeneous as possible would 
be  to  promote  genetic  homogenization  of  study 
populations so that associations are easier to detect. But 
for  CNVs  and  missense  mutations  in  some  genes, 
collections  of  the  same  CNV  or  same  mutation  are 
already  genetically  homogeneous,  at  least  for  that 
component of the complex polygenic architecture.
The  approach  needs  to  be  turned  upside  down,  by 
adoption  of  a  genotype­first  approach  where  novel 
genomic disorders such as genetic generalized epilepsy 
are  classified  and  defined  by  detection  of  a  common 
deletion or duplication. The collection of large numbers 
of patients with the same CNV genotype but wide variety 
of phenotypes including epilepsy will facilitate genotype­
phenotype  studies  that  might  provide  insight  into  the 
mechanisms that influence phenotype diversity in these 
and other disorders. Conversely, the collection of large 
numbers  of  genetic  generalized  epilepsy  patients  (not 
even  subtyped  into  subsyndromes)  with  significantly 
more  multiple  rare  DNA  sequence  changes  within  the 
same putative epilepsy susceptibility gene, as compared 
with unaffected controls, might be an outcome of their 
pursuit  through  massively  parallel  sequencing.  That 
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just those cases with mutations in a defined susceptibility 
gene  to  see  if  they  have  subtle  phenotypic  features  in 
common.  Thus  might  emerge  a  subsyndrome  classifi­
cation that is different to that currently in use, based on 
more relevant components of the phenotype that better 
reflect the underlying molecular genetics.
Finally, we agree that careful clinical phenotyping is a 
vital component of our research, as the constellations 
associated with each of the CNVs need to be accurately 
characterized.  Consider  cohorts  comprising  15q13.3 
deletions, for example. Some of the cases are regarded 
as  epilepsy  only.  Others  are  regarded  as  having  dual 
pheno  types, of epilepsy and ID, for example. Are these 
really  dual  phenotypes?  Consider  the  hypothetical 
possibility  that  the  haploid  content  of  the  15q13.3 
region lowers the seizure threshold and adversely affects 
intelligence in everyone who carries it. Some carriers 
will not have epilepsy because their susceptibility profile 
contains  too  few  susceptibility  variants  at  other  loci 
throughout the genome, in addition to 15q13.3, to take 
them  across  the  seizure  threshold.  Some  carriers  will 
not have ID because their baseline intelligence quotient 
will be high enough to begin with that even with some 
depression of intelligence quotient through the effects 
of the 15q13.3 deletion they remain within the normal 
range.  Others,  toward  the  lower  end  of  the  normal 
range to begin with, unfortunately drop down into the 
ID range. We challenge the clinical researchers to prove 
us wrong or, like us, seriously question the notion of 
dual  phenotypes  presenting  in  only  a  subset  of  the 
15q13.3 deletion carriers.
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